Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Anti-SS-A/Ro antibody (anti-SSA), the diagnostic marker of Sjögren's syndrome (SS), is often detected in systemic sclerosis (SSc). Some patients are diagnosed with SSc/SS overlap syndromes, while there are anti-SSA-positive SSc cases without SS. In this study, we investigated the clinical characteristics of SSc with anti-SSA and clarified the clinical impact of this antibody in SSc. METHODS: A retrospective chart review was conducted of 156 patients with SSc at Yokohama City University Hospital from 2018 to 2021. Clinical data, laboratory data, imaging, and autoantibody positivity status were collected and analysed to assess the association between these variables and anti-SSA using multivariable logistic regression analysis. RESULTS: This cohort included 18 men and 138 women with SSc (median age, 69.0 years). Thirty-nine patients had diffuse cutaneous SSc (dcSSc) (25%), and 117 patients had limited cutaneous SSc (75%). Forty-four patients were anti-SSA-positive. Among them, 24 fulfilled the SS criteria. Multivariable logistic regression revealed that anti-SSA was statistically associated with interstitial lung disease (ILD; odds ratio [OR] = 2.67; 95% confidence interval [CI], 1.14-6.3; P = 0.024). Meanwhile, anti-SSA positivity tended to increase the development of digital ulcer (OR = 2.18; 95% CI, 0.99-4.82, P = 0.054). In the comparative analysis of the autoantibody single-positive and anti-SSA/SSc-specific autoantibody double-positive groups, the anti-SSA single-positive group showed a significantly increased risk of ILD (OR = 12.1; 95% CI, 2.13-140.57; P = 0.003). Furthermore, patients with SSc and anti-SSA indicated that anti-SSA-positive SSc without SS was strongly associated with dcSSc when compared to that in patients with SS (OR = 6.45; 95% CI, 1.23-32.60; P = 0.024). CONCLUSIONS: Anti-SSA positivity increases the risk of organ involvement, such as ILD, in patients with SSc. Additionally, the anti-SSA-positive SSc without SS population may have more severe skin fibrosis than others. Anti-SSA may be a potential marker of ILD and skin severity in SSc.

DOI： 10.1186/s13075-024-03325-6

PubMed

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：Japanese   Publisher：(一社)日本リウマチ学会  

researchmap

Language：Japanese   Publisher：(一社)日本リウマチ学会  

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Enhanced circulating blood periostin levels positively correlate with disease severity in patients with systemic sclerosis (SSc). Monocytes/macrophages are predominantly associated with the pathogenesis of SSc, but the effect of periostin on immune cells, particularly monocytes and macrophages, still remains to be elucidated. We examined the effect of periostin on monocytes and monocyte-derived macrophages (MDM) in the pathogenesis of SSc. The modified Rodnan total skin thickness score in patients with dcSSc was positively correlated with the proportion of CD80-CD206+ M2 cells. The proportion of M2 macrophages was significantly reduced in rPn-stimulated MDMs of HCs compared to that of SSc patients. The mRNA expression of pro-fibrotic cytokines, chemokines, and ECM proteins was significantly upregulated in rPn-stimulated monocytes and MDMs as compared to that of control monocytes and MDMs. A similar trend was observed for protein expression in the respective MDMs. In addition, the ratio of migrated cells was significantly higher in rPn-stimulated as compared to control monocytes. These results suggest that periostin promotes inflammation and fibrosis in the pathogenesis of SSc by possible modulation of monocytes/macrophages.

DOI： 10.1371/journal.pone.0281881

PubMed

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Monocytes and macrophages are implicated in inflammation and atherosclerosis, whereas monocytes are involved in psoriasis lesion formation. We previously reported a psoriatic inflammation-associated significant decrease in the membrane protein caveolin-1 (CAV-1) in psoriasis patient monocytes. However, the phenotype of circulating monocytes and their macrophage differentiation in psoriasis patients remain unclear. OBJECTIVE: We sought to clarify circulating monocyte and monocyte-derived macrophage (MDM) phenotypes in psoriasis patients with and without comorbidities. METHODS: Thirty-one patients with psoriasis vulgaris and 28 control subjects were included. Surface macrophage markers and inflammatory status were examined in circulating monocytes and MDMs from both groups. Expression of CD36, which mediates macrophage uptake of oxidized low-density lipoprotein (oxLDL), was evaluated in these cells. CAV-1-silenced monocytes were differentiated into macrophages to investigate the effects of CAV-1 downregulation on psoriatic inflammation and atherosclerosis. RESULTS: Macrophage surface markers were detectable in circulating monocytes. A significant M1 shift was detected in monocytes and MDMs in psoriasis patients, including those without cardiovascular disease risk factors, as compared to controls. MDMs of psoriasis patients had more CD36-expressing cells, which are associated with atherosclerosis risk. Additionally, CAV-1-silencing in monocytes increased the likelihood of M1-biased macrophage differentiation and increased pro-inflammatory cytokine production. CONCLUSIONS: Monocytes from psoriasis patients were more likely to differentiate into M1-dominant macrophages, correlating with inflammatory status and CAV-1 expression. These aberrant inflammatory monocytes not only contribute to psoriatic inflammation by producing psoriatic cytokines, but also have a phenotype that could increase atherosclerosis risk by uptake of oxLDL and formation of foam cells.

DOI： 10.1016/j.jdermsci.2022.07.003

PubMed

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：Japanese   Publisher：(一社)日本アレルギー学会  

researchmap

Authorship：Lead author   Publishing type：Research paper (scientific journal)   Publisher：Elsevier {BV}  

DOI： 10.1016/j.jid.2021.02.015

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Oxford University Press (OUP)  

DOI： 10.1093/rheumatology/keaa112

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本リウマチ学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Wiley  

Dermatomyositis (DM) is an autoimmune inflammatory disease characterized by skin eruptions and myositis. Anti-transcriptional intermediary factor 1-γ antibody (anti-TIF1-γ Ab) is one of the most frequently detected myositis-specific autoantibodies and adults positive for anti-TIF1-γ have markedly higher rates of malignancy. Our aim was to determine the clinical associations of anti-TIF1-γ levels in 31 Japanese adult DM patients positive for anti-TIF1-γ. We determined associations between the anti-TIF1-γ index and patient characteristics and disease severities. Sixteen patients with anti-TIF1-γ Ab had concomitant malignancies. A mild positive correlation was found between the levels of serum creatine phosphokinase at the first visit and anti-TIF1-γ levels. In contrast, there was no significant difference in the anti-TIF1-γ Ab index between patients with and without malignancy. Dysphagia tended to be observed in patients with malignancy. On sequential analysis, anti-TIF1-γ levels in patients without malignancy were lower or turned negative after treatment for DM. Ab titers tended to be sustained in patients with stage IV malignancies. Interestingly, a re-increase in the Ab titer was observed on recurrence of malignancy or increase in DM activity. Four patients were completely cured of their malignancies, and anti-TIF1-γ levels in three patients turned negative with the loss of DM activity. These data suggest that higher anti-TIF1-γ titers may not directly indicate the presence of malignancy. Nevertheless, longitudinal changes in the anti-TIF1-γ index in individual patients may partially reflect activities of both DM and malignancy.

DOI： 10.1111/1346-8138.15284

PubMed

researchmap

Other Link： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/1346-8138.15284

Language：Japanese   Publisher：(一社)日本皮膚免疫アレルギー学会  

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Wiley  

Hydroxychloroquine is recommended as the first-line systemic treatment for cutaneous lupus erythematosus (CLE) in Western countries, and it was approved in Japan in 2016. However, the efficacy of hydroxychloroquine in various cutaneous lupus erythematosus subtypes in Japanese patients has not been elucidated to date. Therefore, we investigated the efficacy of hydroxychloroquine for the treatment of cutaneous manifestations according to CLE subtypes in Japanese patients. We enrolled 35 patients (29 diagnosed with systemic lupus erythematosus and six with CLE) in this retrospective study. We analyzed the efficacy of hydroxychloroquine for the treatment of cutaneous manifestations according to cutaneous lupus erythematosus subtypes, time to the first skin improvement, as well as effects on laboratory data and reduction of concomitant immunosuppressive drug administration at 16 and 32 weeks of therapy. Complete improvement was observed at high rates for acute CLE (ACLE); however, partial or non-improvement rates were higher for chronic CLE (CCLE) at 16 weeks. Several patients with alopecia without scarring achieved complete improvement at 32 weeks. CCLE tended to take more time to improve than ACLE. Overall, hydroxychloroquine was highly effective for skin: 87% of patients had at least some beneficial response at 16 weeks. Nevertheless, there were wide variations in complete improvement rates and duration for improvement among CLE subtypes. Our findings suggest that a therapeutic approach considering the subtypes of CLE will improve its management.

DOI： 10.1111/1346-8138.14802

PubMed

researchmap

Other Link： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/1346-8138.14802

Language：Japanese   Publisher：(一社)日本リウマチ学会  

researchmap

Language：Japanese   Publisher：(一社)日本リウマチ学会  

researchmap

Authorship：Lead author   Language：Japanese   Publisher：(株)協和企画  

＜文献概要＞症例のポイント ・川崎病の経過中に結節性紅斑様皮疹と全身のlivedo racemosaを伴った症例を経験した.・皮膚生検では皮下脂肪織隔壁内の動静脈炎,および動脈周囲を中心とした炎症細胞浸潤を認めた.・川崎病に伴う皮膚血管炎によりこれらの皮疹が生じたと考えた.

researchmap

Language：Japanese   Publisher：(一社)日本皮膚免疫アレルギー学会  

researchmap

Language：Japanese   Publisher：(一社)日本皮膚免疫アレルギー学会  

researchmap

Authorship：Lead author   Language：Japanese   Publisher：(一社)日本皮膚免疫アレルギー学会  

症例は74歳男性で、緑内障に対してラタノプロスト・チモロールマレイン酸塩配合点眼液、ブリンゾラミド点眼液、ジクアホソルナトリウム点眼液、精製ヒアルロン酸ナトリウム点眼液により加療した。効果不十分のためリパスジル塩酸塩水和物点眼液を開始し、眼瞼周囲の紅斑と腫脹が出現した。ベタメタゾン・d-クロルフェニラミンマレイン酸塩配合剤、セチリジン塩酸塩錠、ベタメタゾン吉草酸エステル・ゲンタマイシン硫酸塩軟膏で症状はいったん改善したが、その後、再燃を繰り返した。下眼瞼主体の両側上下眼瞼の紅斑、腫脹、内眼角から鼻唇溝にかけて帯状に流れるような紅斑を認めた。使用中の点眼薬5種類についてパッチテストおよびスクラッチパッチテストを施行した。48時間後判定ではリパスジル塩酸塩水和物点眼液のスクラッチパッチテストが陽性となり、さらに72時間後判定では同点眼液のパッチテストも陽性となった。リパスジル塩酸塩水和物点眼液による接触皮膚炎と診断し、同点眼液を中止した。眼瞼の皮疹は軽快し、その後皮疹の再燃は認めていない。さらに成分パッチテストではリパスジル塩酸塩のみが陽性となった。

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2018&ichushi_jid=J07057&link_issn=&doc_id=20180807470007&doc_link_id=%2Fdl4menek%2F2018%2F000103%2F007%2F0207-0212%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdl4menek%2F2018%2F000103%2F007%2F0207-0212%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：Japanese   Publisher：(一社)日本リウマチ学会  

researchmap

Authorship：Lead author   Language：Japanese   Publisher：(株)協和企画  

＜症例のポイント＞Behcet病とほぼ同時期に発症したと考えられる尋常性乾癬の症例を報告した。Behcet病の病勢と一致して尋常性乾癬の皮疹の改善と悪化がみられた。両疾患の病勢が一致していたことについて、IL-23/Th17軸を介した共通の免疫変調の関与が推察された。(著者抄録)

researchmap

Language：Japanese   Publisher：(一社)日本皮膚アレルギー・接触皮膚炎学会  

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

DOI： 10.1016/j.alit.2015.06.006

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本皮膚免疫アレルギー学会  

症例は79歳男性で、非結核性抗酸菌症に対しクラリスロマイシン、エタンブトールによる内服加療中に血痰、炎症反応上昇を認め、シタフロキサシン内服を開始した。屋外で作業の翌日、顔面、手背に皮疹が出現した。薬疹を疑い、クラリスロマイシン、エタンブトール、シタフロキサシンを中止した。薬剤リンパ球刺激試験は、被疑薬である3剤ともすべて陰性であった。光線テストは、体内から薬剤が消失したと考えられる状態で施行し、3剤ともすべて陰性であった。内服中止、遮光指導にて皮疹はすみやかに消退した。クラリスロマイシン、エタンブトールを再開したが皮疹の再燃はみられなかった。その後、血痰の出現、炎症反応上昇を再度認め、シタフロキサシン内服を再開した。屋外で畑仕事を行ったところ、顔面、手背にそう痒を伴う皮疹が出現した。露光部に日焼け様の紅斑を認めた。経過よりシタフロキサシンによる光線過敏型薬疹を強く疑い、内服を中止したところ、皮膚症状はすみやかに消退した。シタフロキサシン内服照射試験においてUVA照射で陽性となり、シタフロキサシンによる光線過敏型薬疹と診断した。

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2018&ichushi_jid=J07057&link_issn=&doc_id=20180517410007&doc_link_id=%2Fdl4menek%2F2018%2F000102%2F007%2F0124-0128%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdl4menek%2F2018%2F000102%2F007%2F0124-0128%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：Japanese   Publisher：(一社)日本リウマチ学会  

researchmap

Language：Japanese   Publisher：(株)協和企画  

researchmap

Language：Japanese   Publisher：(一社)日本皮膚アレルギー・接触皮膚炎学会  

researchmap

Language：English   Publishing type：Research paper, summary (international conference)   Publisher：WILEY  

Web of Science

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：Japanese  

CiNii Books

researchmap

Other Link： http://search.jamas.or.jp/link/ui/2017275605

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：Japanese   Publisher：(一社)日本皮膚アレルギー・接触皮膚炎学会  

researchmap

Language：Japanese   Publisher：(一社)日本皮膚アレルギー・接触皮膚炎学会  

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：Japanese   Publisher：(一社)日本皮膚アレルギー・接触皮膚炎学会  

researchmap

Language：English   Publishing type：Research paper, summary (international conference)   Publisher：WILEY-BLACKWELL  

Web of Science

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：Japanese   Publisher：(一社)日本神経治療学会  

researchmap